Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto

Sep 02 2016

• By Bridget Silverman

Related Content

Neurocrine Gets First Drug For Tardive Dyskinesia To FDA

Aug 30 2016

Amgen's Blincyto Adds Pediatric Claim For Leukemia

Sep 01 2016

Keeping Track: A Good Week For Biologics And Probuphine, Less So For Eteplirsen And ZS-9

May 30 2016

Keeping Track: FDA Approves Epclusa, Designates Four Breakthrough Therapies, Files Burst Of Applications

Jul 04 2016

Keeping Track: <em>Tecentriq</em>, <em>Opdivo</em> Approvals Intensify Spotlight On Immuno-Oncology

May 23 2016

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Aug 31 2016

Pediatric Study Requirements For Cancer Have FDA Support, But Pose Industry Challenges

Aug 03 2016

Teva CRL Response For Huntington’s Drug Targeted For September

Aug 04 2016

Keeping Track: Mitsubishi ALS NDA; Opko’s Rayaldee Approval; Avycaz Label Extension

Jun 27 2016

Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road

Jun 20 2016

Ariad Narrows Geographic Reach To Maximize Commercial Resources

Jun 21 2016

Related Companies

Novartis AG

Amgen, Inc.

Novartis AG

Neurocrine Biosciences, Inc.

ARIAD Pharmaceuticals, Inc.

Marathon Pharmaceuticals LLC

Mitsubishi Tanabe Pharma Corporation

Array BioPharma, Inc.

Eli Lilly and Company

Boehringer Ingelheim GmbH

Celltrion, Inc.

Johnson & Johnson

Teva Pharmaceutical Industries Ltd.

CSL Limited

Novartis AG

CSL Limited

Kamada Ltd.

Kedrion S.p.A.

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window